Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma
Webcast to be held at 08.30 CEST on Wednesday 6 JulyOslo, Norway, 5 July 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors (Board) has taken the difficult decision to discontinue the study. No further patients will be enrolled into PARADIGME. The